FDA Drug Recalls

Recalls / Class II

Class IID-1333-2020

Product

metFORMIN HCL ER 500 mg, a) 30 tablets (NDC 72789-009-30); b) 60 tablets (NDC 72789-009-60); c) 90 tablets (NDC 72789-009-90); d) 180 tablets (NDC 72789-009-93); e) 100 tablets (NDC 49483-0623-01) bottles, Rx only PD-Rx Pharmaceuticals Incorporated, Oklahoma City, OK 73127

Brand name
Metformin Hydrochloride Extended Release
Generic name
Metformin Hydrochloride
Active ingredient
Metformin Hydrochloride
Route
Oral
NDC
72789-009
FDA application
ANDA090295
Affected lot / code info
Lots: a) A20B02, I19D03, J19A98, K19E32, L19C86 Exp. 12/31/2020; b) I19D55, I19F50, K19A18, K19D87, L19B34, L19D23, L19E74 Exp. 12/31/2020; c) I19E91, I19F33, J19B88, J19E70, K19D26, L19A65 Exp. 12/31/2020; d) I19C21 Exp. 08/21/2020, I19C57, J19C21, J19C67, K19B53, L19C77, L19E44 Exp. 12/31/2020; e) XP9004 Exp. 12/31/2020

Why it was recalled

CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level

Recalling firm

Firm
PD-Rx Pharmaceuticals, Inc.
Notification channel
Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Type
Voluntary: Firm initiated
Address
727 N Ann Arbor Ave, N/A, Oklahoma City, Oklahoma 73127-5822

Distribution

Quantity
1969 bottles
Distribution pattern
United States.

Timeline

Recall initiated
2020-06-05
FDA classified
2020-06-20
Posted by FDA
2020-07-01
Terminated
2021-11-08
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-1333-2020. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.